Eli Lilly & Co.'s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

In Q2, it brought in $11.3 billion in sales, 36% higher than a year prior, and it cranked up its annual revenue guidance for ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

Pharma stocks have been on quite a nice run over the past year. A number of new catalysts have revitalized this sector, which ...

Last month, Eli Lilly announced it would reduce the cost of the lowest dose of its drug Zepbound to around $400 a month. It also launched its own telehealth company, LillyDirect. Readdy ...

If anything, the four-week supply of the 2.5 mg Zepbound single-dose vial at $399 (self-pay) is not too far from HIMS' compounded GLP-1 injectables from $199 monthly (based on a 12-month plan).

When I was single I barely got noticed. I don’t like this attention, but is it normal?” It piqued my interest, so I put up a poll asking: “Men … did you notice more women hit on you post ...

Eli Lilly, for example, recently announced that they would be selling vials of Zepbound (for weight loss) and Mounjaro (for type 2 diabetes) directly to consumers, which will half the cost of the ...

Compounding pharmacies have used a legal provision that allows them to make knockoff versions of Lilly’s Zepbound and Mounjaro while they are in a shortage. While Lilly has raised questions ...